Hexa Health Care Private Limited

Hexa Health Care Private Limited, established on May 24, 2005, is a private limited company headquartered in Mumbai, Maharashtra, India. The company is registered under the Corporate Identification Number (CIN) U24230MH2005PTC153478. Its authorized capital is ₹5.00 million, with a paid-up capital of ₹3.20 million. The registered office is located at Bhiwandiwala Building, 194 Dattaram Lad Marg, Kalachowki, Mumbai, Maharashtra, 400033.

Hexa Health Care Private Limited operates in the pharmaceutical sector, focusing on the manufacturing and export of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. The company is unlisted and has been active in the industry for over two decades. As of November 3, 2025, the company is led by two directors: Niren Mansukhlal Shah and Piyush Bharat Shah.

Specific details regarding Hexa Health Care Private Limited's manufacturing facilities, including their locations, capacities, and specializations, are not publicly disclosed. The company is registered under the Corporate Identification Number (CIN) U24230MH2005PTC153478, indicating its involvement in the manufacturing of pharmaceuticals, medicinal chemicals, and botanical products.

The leadership team of Hexa Health Care Private Limited comprises:

• Niren Mansukhlal Shah: Director since May 24, 2005.

• Piyush Bharat Shah: Additional Director since November 26, 2024.

Hexa Health Care Private Limited's presence in regulated markets such as the United States, European Union, United Kingdom, Australia, and Japan is not publicly documented. The company's export activities, as per TransData Nexus proprietary trade data, amount to $1.0 million USD across 349 shipments, with a portfolio concentration of 99.3% in its top five products. However, specific regulatory filings, approvals, and market access statuses in these regions are not available in the provided sources.

The company's export data indicates a significant focus on the Diabetes & Endocrine therapeutic category, accounting for 65.2% of its exports. This suggests potential penetration into emerging markets where diabetes prevalence is rising. However, specific information regarding the company's presence in Africa, Latin America, or Southeast Asia, and whether it holds WHO prequalification for these regions, is not available in the provided sources.

Hexa Health Care Private Limited's export portfolio is highly concentrated, with its top five products comprising 99.3% of total exports. This indicates a focused geographic strategy, potentially targeting markets with high demand for these specific products. However, the lack of detailed information on the company's geographic diversification and strategic direction limits a comprehensive assessment of its concentration risk and future outlook.

Specific details regarding Hexa Health Care Private Limited's FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history are not publicly available. The company's export data does not provide insights into its regulatory standing with the U.S. Food and Drug Administration (FDA).

Information regarding Hexa Health Care Private Limited's compliance with World Health Organization (WHO) prequalification, European Union Good Manufacturing Practice (EU GMP) certificates, or European Directorate for the Quality of Medicines & HealthCare (EDQM) status is not available in the provided sources.

Specific details about Hexa Health Care Private Limited's manufacturing licenses from the Central Drugs Standard Control Organisation (CDSCO), approvals from state drug controllers, or export No Objection Certificates (NOCs) are not publicly disclosed. The company's registration under CIN U24230MH2005PTC153478 indicates its compliance with Indian regulatory requirements for pharmaceutical manufacturing.

There is no publicly available information regarding any Form 483 observations, warning letters, or import alerts issued to Hexa Health Care Private Limited. The company's export data does not indicate any regulatory challenges or compliance issues.

Hexa Health Care Private Limited operates in the pharmaceutical sector, competing with various domestic and international companies. However, specific information regarding its top competitors in overlapping categories, market share comparisons, and head-to-head analyses is not available in the provided sources.

Hexa Health Care Private Limited's key differentiators include its focused product portfolio, with a significant emphasis on the Diabetes & Endocrine therapeutic category, and its extensive experience in the pharmaceutical manufacturing sector. However, detailed insights into its unique strengths, competitive advantages, and product portfolio distinctions are limited due to the lack of comprehensive public information.

The company's strategic direction appears to be focused on the manufacturing and export of finished pharmaceutical formulations, particularly in the Diabetes & Endocrine therapeutic category. However, without detailed information on its product development pipeline, market expansion plans, or future outlook, a comprehensive assessment of its current strategic position and future direction is not feasible.

Hexa Health Care Private Limited's export data indicates a consistent volume of shipments, with a total of 349 shipments valued at $1.0 million USD. The portfolio concentration of 99.3% in its top five products suggests a focused approach to its export activities. However, without detailed information on the company's supply chain practices, quality control measures, and reliability indicators, a thorough assessment of its overall track record and consistency as a supplier cannot be conducted.

Importers considering Hexa Health Care Private Limited as a supplier should verify the following certifications:

• FDA Registration: Confirm the company's registration status with the U.S. Food and Drug Administration to ensure compliance with U.S. regulatory standards.

• WHO-GMP Certification: Verify the company's compliance with World Health Organization Good Manufacturing Practice standards to ensure product quality and safety.

• EU GMP Certification: Confirm the company's adherence to European Union Good Manufacturing Practice standards, which are recognized globally for pharmaceutical manufacturing.

• ISO Certification: Check for ISO certifications related to quality management systems, which indicate a commitment to maintaining high-quality standards.

To verify these certifications, importers should request copies of the certificates directly from Hexa Health Care Private Limited and cross-reference them with the issuing authorities' official records.

Importers should undertake the following steps to ensure a comprehensive due diligence process when considering Hexa Health Care Private Limited as a supplier:

• Verify Regulatory Compliance: Confirm the company's compliance with relevant regulatory bodies, including the FDA, WHO, EU GMP, and ISO standards.

• Assess Financial Stability: Review the company's financial statements to evaluate its financial health and stability.

• Evaluate Manufacturing Capabilities: Assess the company's manufacturing facilities, including their capacity, quality control measures, and adherence to Good Manufacturing Practices.

• Review Product Portfolio: Examine the company's product offerings to ensure they meet the required specifications and quality standards.

• Check References and Reputation: Seek references from other clients and review the company's reputation in the industry to gauge reliability and trustworthiness.

Red flags to watch for include discrepancies in certification documents, financial irregularities, or negative feedback from previous clients. Recommended pre-order checks involve conducting site visits to manufacturing facilities, reviewing quality control processes, and ensuring clear communication channels with the supplier.